Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics, Inc.

GLUENYSE / NASDAQHealthcareSmall cap

$8.64-$0.27 (-3.0%)

Last close · Data as of Nov 20, 2026

Market cap
$1.5B
P/E
-38.0x
EV / EBITDA
-30.0x
Revenue
$123.7M
Net margin
-31.2%
ROCE
-14.1%

-36.1% over the last year

Monte Rosa Therapeutics, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-23.9%
3M
-41.5%
6M
-53.7%
1Y
-36.1%
5Y
-55.9%

52-week range

Day change -$0.27 (-3.0%) from $9 to $9 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in GLUE, bought on each weekday since 2021.

News & filings

What Monte Rosa Therapeutics filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 38.6 million US dollars in fiscal 2025.

Strengths (1)

  • Revenue grew 63.5% in fiscal 2025.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins.

Read moreShow less

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1a, IL-1ß and IL-18, as well as damage-associated molecular patterns. In addition, it develops CDK2 to treat multiple cancers, including ovarian, endometrial, gastric and breast. Further, its pipeline includes programs in immunology and inflammation indications, oncology, cardiovascular, metabolic, and genetic diseases. The company also develops QuEEN, a discovery engine, to enable its target-centric MGD discovery and development approach and its rational design of MGD product candidates. It has a strategic collaboration and licensing agreement with F. Hoffmann-La Roche Ltd.; and Novartis. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

Sector
Healthcare
Shares outstanding
65.5M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$1.5B
P/E
-38.0x
P/B
6.3x
EV / EBITDA
-30.0x
EV / Sales
11.1x
P/S
11.9x
52-week high
$25.31
52-week low
$8.64

Profitability

Operating margin
-43.8%
Net margin
-31.2%
EBITDA margin
-37.1%
ROE
-16.6%
ROCE
-14.1%
ROIC
-30.1%
ROA
-8.6%
Asset turnover
0.28

Growth

Revenue
$123.7M
Revenue growth, 1Y
63.5%
Net profit growth, 1Y
-46.9%
Free cash flow
-$27.5M

Solvency

Current ratio
6.12
Debt / Equity
0.17
Debt / Assets
0.09
CFO / Net profit
0.59
Cash / Market cap
8.9%

Where the revenue went

FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.

LineFY2025
Revenue$123.7M
Gross profit$123.7M
Operating expenses$177.9M
Research and development$141.5M
Selling, general and administrative$36.4M
Operating income-$54.2M
Interest and other$14.5M
Pretax income-$39.7M
Tax and other-$1.1M
Net income-$38.6M

Revenue and net profit

Revenue grew 63.5% in FY2025; net profit is the dashed line.

Monte Rosa Therapeutics, Inc. revenue and net profit by fiscal year
Monte Rosa Therapeutics, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$0.00-$108.5M
FY2023$0.00-$135.4M
FY2024$75.6M-$72.7M
FY2025$123.7M-$38.6M

Cash flows

FY2025: -$22.8M from operations, -$27.5M free after investment (dashed).

Monte Rosa Therapeutics, Inc. operating and free cash flow by fiscal year
Monte Rosa Therapeutics, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$92.5M-$105.4M
FY2023-$43.8M-$62.8M
FY2024$42.0M$38.0M
FY2025-$22.8M-$27.5M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$123.7M+63.5%1Y
EBITDA
-$45.9M
Net profit
-$38.6M
Cash from operations
-$22.8M-154.3%1Y
Free cash flow
-$27.5M-172.3%1Y
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$123.7M-$45.9M-$38.6M-$27.5M-16.6%+63.5%-46.9%

Monthly returns

Month-by-month returns of GLUE across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$448.7M
Liabilities$215.6M
Equity$233.1M
Paid-in capital$714.1M
Retained earnings-$477.2M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; GLUE highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

EV / Sales, for the companies without earnings

  1. Monte Rosa Therapeutics, Inc. (this company)11.1x

Not shown (no positive earnings and no EV / Sales): MBX Biosciences, Inc., Maze Therapeutics, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Monte Rosa Therapeutics, Inc.GLUEthis company$1.5B-38.0x6.3x-16.6%-30.0x
AnaptysBio, Inc.ANAB$1.5B—40.4x-35.6%17.4x
STAAR Surgical CompanySTAA$1.5B-18.5x4.3x-23.4%-36.9x
Perrigo Company plcPRGO$1.5B-1.0x0.5x-48.6%-5.7x
NeoGenomics, Inc.NEO$1.5B-13.6x1.8x-12.9%-44.5x
MBX Biosciences, Inc.MBX$1.5B-16.9x4.0x-23.6%-14.3x
Aveanna Healthcare Holdings Inc.AVAH$1.4B6.4x7.4x115.3%10.3x
Septerna, Inc.SEPN$1.4B-28.9x3.7x-12.8%-16.6x
Maze Therapeutics, Inc.MAZE$1.4B-10.7x4.0x-36.9%-8.8x
Peer median—-13.6x4.0x-23.5%-11.6x

Year-to-date ROI

GLUE since 1 January, against earlier years.

Historical volatility

GLUE's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Monte Rosa Therapeutics, Inc. operating margin by fiscal year
Monte Rosa Therapeutics, Inc. operating margin by fiscal year
DateOperating margin
FY2024-107.3%
FY2025-43.8%
LineFY2025
Operating expensesOperating Expense$177.9M
Research and developmentResearch And Development$141.5M
Total expensesTotal Expenses$177.9M
Pretax incomePretax Income-$39.7M

Learn while you research

Academy chapters picked for Monte Rosa Therapeutics, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Growth Investing64% revenue growth is in the top tier, learn how to value growth.7 min read
  3. 03 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  4. 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  5. 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  6. 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →